Quality of life improved for patients after starting dialysis but is impaired, initially, for their partners: a multi-centre, longitudinal study.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
18 05 2020
Historique:
received: 12 01 2020
accepted: 19 04 2020
entrez: 20 5 2020
pubmed: 20 5 2020
medline: 10 9 2021
Statut: epublish

Résumé

Quality of life (QOL) is important to patients with end stage renal disease and their partners. Despite the first 12 weeks being a critical time in the treatment pathway, limited research exists which examines how the transition onto dialysis impacts QOL. In this study we measured QOL in patients and their partners at pre-dialysis and over the first 12 weeks on dialysis to investigate QOL during this crucial period. Patients and their partners, recruited from 10 renal units in England, completed questionnaires at pre-dialysis (n = 166 participants, 83 couples), 6 weeks (n = 90 participants, 45 couples) and 12 weeks (n = 78, 39 couples) after starting dialysis. On each occasion participants completed a QOL questionnaire (WHOQOL-BREF). Multilevel modelling accommodated the nested structure of couples with repeated measures within participants. Three-level random intercept models estimated changes in WHOQOL general QOL and its four domains (Physical, Psychological, Social and Environment). Two-level random intercept models assessed the relationship between baseline clinical and socio-demographic variables with changes in general QOL. Patients reported positive changes in general QOL from pre-dialysis to 6 weeks (β = 0.42, p < 0.001, 95% CI 0.19, 0.65) and from pre-dialysis to 12 weeks (β = 0.47, p < 0.001, 95% CI 0.24, 0.71). Partners' general QOL decreased significantly from pre-dialysis to 6 weeks (β = - 0.24, p = 0.04, 95% CI -0.47, - 0.01) but returned to its original level at 12 weeks. Patients reported improvements in the physical domain between pre-dialysis and 12 weeks (β = 6.56, p < 0.004, 95% CI 2.10, 11.03). No other domains changed significantly in patients or partners. Only in patients were there significant associations between moderator variables and general QOL. High comorbidity risk level and diabetes were associated with poorer QOL at pre-dialysis whereas being female and having an arteriovenous fistula were linked with improvements in general QOL. Patients reported significant improvements in their general and physical QOL after starting dialysis. Partners' general QOL worsened after patients started dialysis but improved by 12 weeks. Both patients and partners may benefit from additional educational and counselling services in the lead up to, and immediately after starting dialysis, which could facilitate the transition onto dialysis and improve QOL in both. This study was adopted on the NIHR Clinical Research Network (UK). The details of this study are registered on the Research Registry website (www.researchregistry.com). The identifier for this study is researchregistry2574.

Sections du résumé

BACKGROUND
Quality of life (QOL) is important to patients with end stage renal disease and their partners. Despite the first 12 weeks being a critical time in the treatment pathway, limited research exists which examines how the transition onto dialysis impacts QOL. In this study we measured QOL in patients and their partners at pre-dialysis and over the first 12 weeks on dialysis to investigate QOL during this crucial period.
METHODS
Patients and their partners, recruited from 10 renal units in England, completed questionnaires at pre-dialysis (n = 166 participants, 83 couples), 6 weeks (n = 90 participants, 45 couples) and 12 weeks (n = 78, 39 couples) after starting dialysis. On each occasion participants completed a QOL questionnaire (WHOQOL-BREF). Multilevel modelling accommodated the nested structure of couples with repeated measures within participants. Three-level random intercept models estimated changes in WHOQOL general QOL and its four domains (Physical, Psychological, Social and Environment). Two-level random intercept models assessed the relationship between baseline clinical and socio-demographic variables with changes in general QOL.
RESULTS
Patients reported positive changes in general QOL from pre-dialysis to 6 weeks (β = 0.42, p < 0.001, 95% CI 0.19, 0.65) and from pre-dialysis to 12 weeks (β = 0.47, p < 0.001, 95% CI 0.24, 0.71). Partners' general QOL decreased significantly from pre-dialysis to 6 weeks (β = - 0.24, p = 0.04, 95% CI -0.47, - 0.01) but returned to its original level at 12 weeks. Patients reported improvements in the physical domain between pre-dialysis and 12 weeks (β = 6.56, p < 0.004, 95% CI 2.10, 11.03). No other domains changed significantly in patients or partners. Only in patients were there significant associations between moderator variables and general QOL. High comorbidity risk level and diabetes were associated with poorer QOL at pre-dialysis whereas being female and having an arteriovenous fistula were linked with improvements in general QOL.
CONCLUSIONS
Patients reported significant improvements in their general and physical QOL after starting dialysis. Partners' general QOL worsened after patients started dialysis but improved by 12 weeks. Both patients and partners may benefit from additional educational and counselling services in the lead up to, and immediately after starting dialysis, which could facilitate the transition onto dialysis and improve QOL in both.
STUDY REGISTRATION
This study was adopted on the NIHR Clinical Research Network (UK). The details of this study are registered on the Research Registry website (www.researchregistry.com). The identifier for this study is researchregistry2574.

Identifiants

pubmed: 32423378
doi: 10.1186/s12882-020-01819-4
pii: 10.1186/s12882-020-01819-4
pmc: PMC7236460
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

185

Subventions

Organisme : Medical Research Council
ID : Doctoral Training Partnership
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Références

J Nephrol. 2004 Nov-Dec;17(6):841-50
pubmed: 15593060
Health Expect. 2012 Mar;15(1):49-62
pubmed: 21281412
Nephrology (Carlton). 2019 Oct;24(10):1056-1063
pubmed: 30723975
Int J Clin Pract. 2013 Apr;67(4):363-8
pubmed: 23521328
J Cogn Dev. 2010;11(2):121-136
pubmed: 21743795
BMC Nephrol. 2008 Nov 14;9:14
pubmed: 19014597
Qual Health Res. 2020 Feb;30(3):380-390
pubmed: 31478450
Qual Life Res. 2004 Mar;13(2):299-310
pubmed: 15085902
Perit Dial Int. 2019 Mar-Apr;39(2):176-180
pubmed: 30858285
Qual Life Res. 2014 Feb;23(1):57-66
pubmed: 23689932
Nephrol Dial Transplant. 2002 Jun;17(6):1085-92
pubmed: 12032201
Lancet. 2016 Jul 16;388(10041):294-306
pubmed: 27226132
Am J Kidney Dis. 2016 Sep;68(3):444-54
pubmed: 26968042
J Am Soc Nephrol. 2004 Mar;15(3):743-53
pubmed: 14978177
Clin J Am Soc Nephrol. 2019 Jan 7;14(1):74-83
pubmed: 30573659
Am J Kidney Dis. 2017 Oct;70(4):464-475
pubmed: 28238554
Kidney Int. 1999 Aug;56(2):720-8
pubmed: 10432414
Front Pharmacol. 2018 Jul 16;9:770
pubmed: 30061835
J Adv Nurs. 2014 Aug;70(8):1902-14
pubmed: 24495288
EDTNA ERCA J. 2005 Jan-Mar;31(1):35-8
pubmed: 16083026
Gen Hosp Psychiatry. 2012 Sep-Oct;34(5):518-24
pubmed: 22401704
Res Theory Nurs Pract. 2004 Spring;18(1):51-72
pubmed: 15083662
Qual Life Res. 2016 Feb;25(2):373-384
pubmed: 26195319
BMC Nephrol. 2019 Apr 29;20(1):144
pubmed: 31035977
Br J Health Psychol. 2018 Sep;23(3):544-560
pubmed: 29508505
BMJ Glob Health. 2018 Jan 6;3(Suppl 1):e000609
pubmed: 29379649
Clin J Am Soc Nephrol. 2007 Jan;2(1):89-99
pubmed: 17699392
J Adv Nurs. 2012 Nov;68(11):2410-7
pubmed: 22360845
Nephrol Dial Transplant. 2008 May;23(5):1713-9
pubmed: 18182410
Nephrol Dial Transplant. 2010 May;25(5):1621-6
pubmed: 20037172
Am J Kidney Dis. 2010 Mar;55(3):431-40
pubmed: 20116914
Am J Kidney Dis. 2006 Dec;48(6):955-63
pubmed: 17162150
Clin J Am Soc Nephrol. 2006 Jul;1(4):802-10
pubmed: 17699290
Qual Life Res. 2020 Jan;29(1):81-89
pubmed: 31792798
Health Qual Life Outcomes. 2006 Apr 25;4:27
pubmed: 16638129
ISRN Nephrol. 2012 Oct 21;2013:308986
pubmed: 24959536
Iran J Kidney Dis. 2011 Jan;5(1):9-14
pubmed: 21189427
BMC Nephrol. 2016 Apr 27;17(1):44
pubmed: 27117687
Semin Nephrol. 2017 Mar;37(2):181-193
pubmed: 28410652
Kidney Int. 1998 Jul;54(1):245-54
pubmed: 9648085
Nephrol Dial Transplant. 2008 Dec;23(12):3749-51
pubmed: 19028759
J Clin Nurs. 2014 Nov;23(21-22):3262-73
pubmed: 24810661
Soc Work Health Care. 1999;30(1):15-30
pubmed: 10855800
Hemodial Int. 2012 Apr;16(2):214-9
pubmed: 22304491
Nephrol Dial Transplant. 2011 Dec;26(12):4038-46
pubmed: 21482637
Mayo Clin Proc. 2002 May;77(5):479-87
pubmed: 12004998
Patient Educ Couns. 2010 Oct;81(1):30-6
pubmed: 19962846
Perit Dial Int. 2003 Dec;23 Suppl 2:S200-5
pubmed: 17986549

Auteurs

Currie Moore (C)

School of Health Sciences, Division of Psychology and Mental Health, Manchester Centre for Health Psychology, University of Manchester, Manchester, UK. currie.moore@postgrad.manchester.ac.uk.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. currie.moore@postgrad.manchester.ac.uk.

Lesley-Anne Carter (LA)

Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, UK.

Sandip Mitra (S)

Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Manchester University NHS Foundation Trust, Manchester, UK.
NIHR Devices for Dignity MedTech Cooperative, Sheffield, UK.

Suzanne Skevington (S)

School of Health Sciences, Division of Psychology and Mental Health, Manchester Centre for Health Psychology, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Alison Wearden (A)

School of Health Sciences, Division of Psychology and Mental Health, Manchester Centre for Health Psychology, University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH